Nonalcoholic steatohepatitis (NASH ... and focus on current discussions related to the specific lesions in the pathology of NASH, including the challenges of pediatric NASH and NASH-related ...
PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted full qualification for ...
EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...
The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...
The tool, called AIM-NASH (Artificial Intelligence-Based Measurement of Non-alcoholic Steatohepatitis Histology) from Boston-based Path AI, supports pathologists in analyzing liver biopsy scans to ...
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...
The EMA CHMP has determined that the proposed Artificial Intelligence-Based Measurement of Non-alcoholic Steatohepatitis Histology (AIM-MASH) tool can be used in metabolic dysfunction associated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback